:\ general procedure for in vitro site-directed mutagenesis of the wild-type dihydropteridine reductase gene has been used successfully to make eight mutant proteins. Five mutations were at the active site, viz Tyrl50His, Tyrl50Ser, Tyrl50Phe, Tyr150Glu and Tyrl50Lys. The proteins were expressed as glutathione S-transferase fusion proteins from which the unconjugated reductases were obtained by thrombin cleavage. The kinetic parameters of the conjugated and unconjugated reductases were measured using natural quinonoid R-7,8(6H)-dihydrobiopterin and non-natural quinonoid 8(6H)-dihydropterin and NADH. The kcat (maximum velocity at saturating concentrations of substrates) and kcatl Km (first order rate constant at low concentration of substrates) values show that the phenolic OH of Tyr 150 was the most likely proton source to complete the hydride reduction of the quinonoid pterin cofactor. However in the absence of a proton source at residue 150, measurable enzyme activities were observed indicating that a proton was relayed via a water molecule(s) from some neighbouring acidic amino acid residue.
Introduction
Dihydropteridine reductase [EC 1.6.99.7] catalyses the reduction of quinonoid 7 ,8( 6H)-dihydropterins (1) to 5,6,7,8-tetrahydropterins (2) and uses NADH as cofactor which is in turn oxidised to NAD (1-3)(Scheme 1). In the absence of enzyme, NADH is also oxidised by quinonoid dihy- § Author to whom correspondence should be addressed.
dropterins to give NAD and tetrahydropterins respectively (4) but at a slower rate. This non-enzymic reaction increases in rate as the pH is lowered and is consistent with a hydride reduction, i.e. NADH transfers a hydride ion to N5 of the quinonoid pterin with protonation taking place most probably on N3 (4) (5) (6) . The protonation on N3 assists the reduction process and we felt that when the enzyme catalyses the reaction then it may be involved in protonating N3 of the pterin in order to Pteridines/ Vol. 7/No. 4 (1) NADH Scheme 1.
~)
HzN~~ H (2) NAD facilitate the reaction. Titration of human dihydropteridine reductase with S,S'-dithiobis(2-nitrobenzoic acid) and p-chloromercuri-benzoate in the presence and absence of ~PtC4 and measuring enzyme activity suggested that at least one cysteine residue was at the active site of the enzyme (7) . Since this residue is acidic and may be the proton source, we replaced the four cysteines of the reductase (at residues 104, 161 and 26 + 85) in turn by in vitro site-directed mutagenesis. The proteins were expressed in E coli, the mutant enzymes were purified and their thermal stabilities and their kinetic parameters were measured. These were compared with the data from the wild-type (Wf) enzyme also similarly expressed in E. coli. Although the thermal stabilities differed from those of the wild-type reductase, the kinetic parameter values (Km and Vmax) for quinonoid 6-methyl-7,8(6H)-dihydropterin and NADH were not significandy different (8) .
In 1992, Varughese et al. (9) reported the crystal structure of the binary complex of dihydropteridine reductase and NADH from rat, and that their model predicted that N3 and the 2NH z of quinonoid -dihydrobiopterin were exposed to the solvent, also that there was considerable tolerance for the substituent at C6 at the active site (cf kinetic data in refs [10] [11] [12] . They suggested that protonation of the pterin in order to complete the reduction was mediated direcdy by the solvent. As the non-enzymic rate at pH 7.4 for the reaction between pterin (1, R = Me) and NADH at the concentrations used in kinetic experiments is slow then we felt that the rate enhancing influence by the enzyme is unlikely to come from the aqueous buffer.
We used the coordinates of the rat enzyme-NADH complex, which are quite similar to those of the human enzyme-NADH complex (13; a tape of the coordinates was kindly provided by Dr Kottayil I. Varughese) and those of tetrahydrobiopterin (14, 15) to make a model of the terPteridines/ Vol. 7/No. 4 nary complex. Since we knew that the 4-pro-S hydrogen of NADH was transferred to NS of the pterin cofactor then it was possible to align NS with pro-S-H4 and C4 of NADH in the model and we defined the relative positions of the pterin and NADH at the active site. On doing so, it was found that the phenolic OH of tyrosine-ISO (in human DHPR) was closest to N3 of the pterin and would be the most likely acidic amino acid residue to assist the reduction reaction by protonating the pterin. When the hydride is transferred to NS of the pterin, a negative charge is generated at N3 resulting in the conjugate base of the tetrahydropterin which has a pKa value of -10.6 (16) . This is compatible with the pKa of the phenolic group bf tyrosine (e.g. pKa of tyrosine amide is 9.89 at 25°) (17) which may well protonate the pterin anion. With this in mind we proceeded to prepare mutant reductases where Try-ISO was replaced in turn by His Ser, Phe, Glu and Lys residues in order to evaluate the effects of these residues at the active site, and obtain further insights into the mechanism of the reaction. During this period, the mutation Tyr 146Phe was reported for the rat reductase expressed in E. coli (equivalent to TyrlS0Phe in human DHPR), and it was said that the mutant enzyme was virtually devoid of activity although it bound to NADH as strongly as the wild-type enzyme (3, 18) . The mutant reductases obtained by replacement of Tyr 150 by the above mentioned six residues are described in this communication as fusion proteins with glutathione S-transferase of Schistosoma faciculata and the kinetic parameters have been determined and compared with those of the wild-type fusion protein. The unconjugated mutant reductases have also been prepared from the fusion proteins by cleavage with thrombin, and their kinetic parameters are compared with those of the wild-type reductase. By using the same common procedures, three mutations GlylSlSer, Gly23Asp and ThrI23-insertion have been carried out and the fusion proteins have been isolated and their kinetic parameters evaluated. These mutations had been identified in children who had phenylketonuria due to dihydropteridine reductase deficiency (19) , and the enzymic properties have been rationalised with the extent of the disease.
Materials and General Methods
Restriction enzymes and related buffers were purchased from Pharmacia, Progen and New Eng-land Biolabs. The mutagenesis kit using pAlter-1 was from Promega. Agarose (Bio-Rad, ultra-pure high strength grade no 162-0125) was DNA grade. LB medium consists of Bacto-tryptone (10 g. DIFCO Laboratories), yeast extract (5 g), NaCI (5 g) in H 2 0 (to I L) and adjusted to pH 7 .5 with 5N NaOH and autoclaved; 2x IT medium contains Bacto-tryptone (16 g), Bacto yeast extract ( 109, D IFCO Laboratories) and N aCI (5 g) in H 2 0 (I L) and autoclaved. Ampicillin (Sigma) when added to these media was at a concentration of 100 J.1g/ml. TE buffer was 10 mM Tris-HCI (pH 8.0) and I mM EDTA (pH 8) and sterilised. SOx TAE buffer (I L) was made from Tris base 1242 g, 2 moles), glacial acetic acid (57.1 ml), ~a2EDTA 2H 2 0 (37.2 g, 0.1 mole), adjusted to pH 8.5 with HCI and H 2 0, autoclaved and kept at room temperature. lOx TBE buffer was made from Tris base (108 g), boric acid (55 g), 200 ml of 0 .5 ~1 EDTA (pH 8.0) and H 2 0 (to make 1 L) and kept at room temperature. These were diluted when required. MTPBS (mouse tonicity phosphate saline buffer) was made from NaCI (17.4 g), Na2 HP0 4 . 12H 2 0 (11.44 g), NaH 2 P0 4 • 2H 2 0 (1.24 g ) and H 2 0 (to make 2 L). All oligonucleotides ( 31-mers) for site-directed mutagenesis and the two 21-mers used as primers for sequencing were synthesised and purified by the ANU Protein-DNA Resource Facility under the directorship of Dr P. J.
Milburn. DNA sequencing reactions were carried out by using primers and dye-terminators in a Corbett Research Thermal Cycler FTS 4000 to amplifY the sequences and the DNA was run on polyacrylamide gels and scanned through a DNA Applied Biosystems (Model 373 A) Autosequencer. All H 2 0 used in large volumes was glass distilled and H 2 0 used in small volumes and enzymic reactions was MilliQ water and filter-sterilised through a 0 .25 J.1m filter and frozen in 1.5 ml aliquots. All centrifugations at 13000 X g were carried out in Eppendorf 5415C microfuges at 40 unless otherwise stated. Small liquid volumes in Eppendorf tubes were mixed by centrifugation for 2 min at room temperature. See Sambrook, Fritsch and Maniatis (20) for related procedures in molecular biology manipulations. Kinetic measurements were made on a Cary 219 double beam spectrophotometer using cuvettes thermostated at 25° and with 1 cm path lengths.
Competent cells
A single colony of E. coli cells from a freshly grown strain on an LB agar plate was used to inoculate LB medium (3 ml) and incubated with shaking at 37° (preferably in a dry rotary incubator) overnight. The culture (I ml) was added to LB medium (100 ml) and incubated at 3r until the OD 600 was 0 .45 to 0.5 absorbance units. The culture was divided into 2 x 50 ml pre-chilled centrifuge tubes (ss-34, Sorvall) and stored on ice for 2 h, then centrifuged at 2400 X g for 15 min at 4°. The supernatant was discarded and the pellets were re-suspended in ice-cold trituration buffer [10 ml; 1M CaCl 2 (20 ml, autoclaved), 700 mM MgCl 2 (20 ml, autoclaved), 400 mM NaOAc (20 ml, adjusted to pH 5.5 with HCI and filter-sterilised) and sterile H 2 0 (140 ml)], shaken gently and further buffer was added to make 50 ml in each tube. The cells were incubated on ice for 45 min then centrifuged at 1500x g for 10 min at 4°. The individual pellets were re-suspended in icecold trituration buffer (10 ml) and 80% glycerol (2.5 ml) was added to give a final concentration of -15%, mixed gently, aliquoted (I ml) and used directly or chilled in liquid N2 and stored at -70°. These cells remained competent for several months.
Preparation of pAlter-l-hDHPR.
The plasmid p-Bluescript containing human dihydropteridine reductase (hDHPR) cDNA in its multiple cloning site (21) (40 /-LI, 15 /-Lg) was mixed with Hinc II (4 J.1l, 32 U) and Bam HI (20 J.1l, 60 U) in One-Phor-All Buffer Plus (7 J.1l of 10 X, Pharmacia) and H 2 0 to a total volume of 70 J.1l, and incubated at 3r until digestion was complete (2 h).
The whole mixture was run on a 0.7% agarose gel [0.7 g/IOO ml of TAE and 10 J.1l (50/-Lg) ethidium bromide per gel] in TAE buffer containing ethidium bromide (50 /-Lg/IOO ml) at -80 V for -1.5 h together with A-Hind III DNA maker. The 1020 bp band was run onto an NA45 strip (Schleicher and Schuell Co) and visualised under a UV-Iamp. The strip was covered with arginine-NaCl solution (400 J.1l; from 87.1 g of arginine and 584 mg of NaCl in 10 ml H 2 0) in an Eppendorf tube and heated at 70°, with occasional shaking for I h. The solution was pipetted into a second tube and absolute EtOH (900 J.1l) wa:> added, mixed by inversion and set aside at -70 0 overnight. This was centrifuged at 13000 x g for 15 min, the supernatant was removed and the residual pellet was dried in air (inverted tube) for 2 h, dissolved in TE buffer (40/-LI) by heating at 70° for 5 min, and the concentration was detenllined (-13 ng/J.1l) . This DNA contained the whole length of hDHPR cDNA.
The The mixtures were incubated at 16° overnight and left at 4° for 4 h and run on 0.7% agarose gels. The DNAs with sizes of 5680 base pair and larger from the ligation mixtures were isolated and transformed into JM 109 competent cells . Thus ca 50 ng of DNA was added to a suspension of competent cells (200 Ill) and dimethyl sulphoxide (3 Ill) on ice and kept at 0° for 30 min, then heat-shocked at 42° for 2 min and placed on ice. LB-glucose (20 mM ) medium [1.5 ml; prepared from 2M glucose (50 Ill; from 9 g in 25 ml H 2 0, warmed to dissolve, cooled and filtered through a 0.25 11m filter) and 5 ml of sterile LB medium] was added, the mixture was gently vortexed and incubated at 37° for 2 h without shaking to express antibiotic resistance . The cultures were centrifuged at 13000 x g for 2 min, and the pellets were resuspended in LB medium (100 Ill ) and aliquots plated on LB plates containing tetracycline (12.5 Ilg/ ml) and treated with X-Gal (100 Ill, 2 mg ) and 100 mM isopropylthiogalactoside (100 Ill) , and incubated at 37° overnight. Typically, experiments from the first three ratios of vector to insert gave 46 to 55 white colonies and 2 to 11 blue colo nies whereas the fourth experiment which contained no insert DNA gave only blue colonies showing that the ratios of vector to insert DNA used did not seriously affect the ligation yields. The white colonies were grown in LB-amp medium and aliquots were stored in 15% glycerol at -70°. Quantities of pAlter-lhDHPR plasmid DNA were isolated by the "Qiagen midi protocol" procedure, dissolved in TE buffer, and the structure was confirmed by Pteridines/ Vol. 7 / No. 4 DNA size and by the DNA fragments formed on restriction enzyme digestion. Transformation into XLl-Blue cells was as efficient, but AN 1459 cells were less efficient.
Preparation of pAlter-l-hDHPR single stranded DNA.
A single colony of JMI09 containing the plasmid pAlter-l -hDHPR was used to inoculate 3 rnl of 2 X IT medium containing tetracycline (37.5Ilg) and incubated at 37° until the OD600 was 1.0, then R 408 helper phage (80 J1l, 1011 pfu/rnl, Promega) was added and the culture was shaken at 37 for 4.5 h. After centrifugation at 3000 x g for 5 min at 4° the supernatant was collected. DNase I (1 mg/rnl) was added to a final concentration of 2 Ilg/rnl, and the mixture was incubated at 37° for 30 min, then heated at 70° for 15 min to destroy residual bacteria and DNase I , centrifuged at 13000 X g, and the supernatant was collected. To this (1.25 rnI) was added polyethylene glycol (250 J1l: from 13 g of PEG 8000 in 100 rnl H 2 0, autoclaved and stored at room temperature ), and set aside for 15 min at room temperature.
The mixture was centrifuged at 13000 X g for 5 min and the pelle ted phage (freed as much as possible from PEG) was resuspended in TE buffer (200 J1l), and TE-buffered phenol (100 Ill, TE saturated with redistilled phenol 1:1 v/ v) was added. The mixture was vortexed for 1 min, set aside for 5 min, vortexed again and cetrifuged again as above . The upper aqueous phase (-175 J1l) was transferred to a clean tube, 3 M NaOAc (20 Ill, pH 5 .5 ) and absolute EtOH (400 Ill) was added and centrifuged for 20 min at 13000 x g . The pellet containing the single stranded DNA was dissolved in TE buffer (20 Ill) and stored at -20" till required.
When run on a 0.7% agarose gel in T AE buffer only one main band appeared and the material was satisfactory for further work. (d) Isolation of pAlter-I-mutant DHPR.-Five of the preceding colonies were used to inoculate separate LB-amp media (25 ml) and incubated at 37° overnight. The plasmid DNA was isolated using the Qiagen (plasmid midi protocol) procedure, dissolved in TE buffer (100 ilL) and aliquots (0.5, 1.0 and 2 Ill) were run on 0.7% agarose gels (0.7 g/IOO ml of 1 x TAE containing IO~, 150llg of ethidium bromide) in 1 x T AE buffer containing ethidium bromide (10 Ilg for 100 ml of buffer) at SO V for 1.5-2 h. Compared with pBluescript DNA and A-Hind III marker DNA (Promega), all the lanes showed that pAlter-I-mutant DNA from the five colonies contained the DHPR insert.
(e) Transformation into JMI09 competent cells, and sequencing of the pAlter-I-mutant DHPR DNA in the clones.-The preceding plasmid DNA (30 Ill) from each of the five colonies was transformed into competent JMI09 cells as above and selected colonies were isolated, grown in culture, and the plasmid DNA was isolated. Two primers were used for sequencing. The first primer AY-IO was a 2I-mer (5'-TGATGCTAGCGCTGGCCTCTI-3 ') which was used to sequence the Tyrl50Phe, T yrl50His, Tyr150Ser, TyrI50Glu, TyrI50Lys, Gly15ISer, and TI23TT (insertion) mutant pAlter-I plasmids, and the second primer AY-ll was a 21-mer (5'-GCTGTICTTCCCAGCCAGGC-3') for sequencing the Gly23Asp mutant plasmid (see Figure 2 ) . The sequencing mix (in duplicate) contained the dye terminator mix (S .O Ill, Applied Biosystems), the AY primer (3.21-11, 3.2 pmoles), pAlter-I -mutant DHPR as template ( I~, 0.5 Ilg) and H 2 0 (7 .S Ilg), and duplicate (2Ilg, 1 Ilg) and H 2 0 (6 .Sllg), and the total volume (20~) was recycled 25 times in a thermal cycler as follows: each cycle was: 94° for 30 sec; 50° for 15 sec and 60° for 4 min . The mixture was added to ice-cold 3 M NaOAc pH 5.5 (2 Ill ) and 95% EtOH (50 Ill), vortexed, kept on ice for 10 min, and centrifuged at 13000x g for 30 min at room temperature . The supernatant was removed carefully and the pellet was washed twice with 70% ice-cold EtOH (250 Ill ) by the procedure where the Eppendorf tube was rotated 180 0 before each centrifugation in order that the pellet moved through the EtOH to the opposite side of the tube. The supernatant was pipetted off and the pellet was dried in a vacuum centrifuge before running on the polyacrylamide gels in the Autosequencer. At least four, and usually five, out of the five clones selected contained the desired mutation.
Construction of pGEX-2T-mutant DHPR·-PAlter-I-mutated DHPR DNA (1351-11, 54 Ilg), Asc I (6 Ill, 6 U , New England Biolabs), lO x New England Biolabs buffer 4 ( I6~) and H 2 0 (3 Ill) were incubated at 37° for 2 h . The mixture was checked for complete digestion on a 0.7% agarose gel and if incomplete a further quantity of Asc I (3 Ill) was added together with fresh lO x Buffer 4 (16 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] , and incubated at 37° for 4 h and checked again. When digestion was complete the mixture was heated at 70° for 10 min to inactivate Asc 1. The mixture (160 Ill ), Sph I (10 Ill, 50 U), lO x New England Buffer 2 (20 Ill) and H 2 0 (10 Ill) were incubated at 37° until digestion was complete (2 h) . The whole digest was run on 0.7% agarose gels in T AE buffer (with ethidium bromide ) giving three bands of 5S00, 4S1 and 415 base pairs as predicted from the plasmid (Scheme 2). The desired 4S1 bp DNA fragment was isolated via NA45 paper (0.45 11m) and arginine-NaCl extractionjEtOH precipitation (above), dissolved in TE buffer and stored at -20° till required.
pGEX-2T-h DHPR DNA (22) was digested with Asc I and Sph I as above and gave two bands on a 0.7% agarose gel viz of 5424 and 481 base pairs. The larger DNA fragment was isolated and dissolved in TE buffer and stored at -20° till required. This large fragment of DNA (1 f.11, 40 ng) as vector and the 481 base pair fragment from the various pAlter-I-mutated DHPR plasmids (1 f,1l, 5 ng), H 2 0 (6 f.11) and master mix [12 f,1l; from 40 f.11 of 2x T4 buffer, 4 f.11 of 10 mM ATP and 4 f.11 (12 U) of T4 ligase] were incubated at 16° overnight, then at 4° for 4 h, then transformed into competent JMI09 cells as above. Several colonies were obtained on LB-amp agar plates. Five clones were chosen and grown in 50 ml LB-amp cultures and aliquots were kept in 15% glycerol stocks at -70°. Plasmid pGEX-2T-mutated DHPR DNAs were isolated from these clones and sequenced using the AY 21-mer oligonucleotides as primers and dye-dideoxy terminator mix as before. Usually all five clones possessed the correct mutation.
Expression of mutated DHPR. -Bacterial colonies OMI09) containing the pGEX-2T-mutated DHPR plasmid were grown in LB-amp cultures (100 ml, then 1 L) and the GST-mutated DHPR fusion proteins were isolated and purified on GS-Agarose beads (Sigma) as before (22) . Unconjugated DHPR proteins were obtained by cleavage with human thrombin and purified as before (22) . The pellet from 1 L of cell culture (2 x YT and using 100 mM of IPTG and no glucose) was suspended in MTPBS (30 ml containing aprotinin 10 f.1g and phenylmethyl sulphonyl fluoride 0.5 mg as protease inhibitors), and the cells were passed through a Ribi Cell Smasher (Sorvall, model F-I), centrifuged at 5000x g and then at 100,000 x g. The supernatant was gently shaken with GS-Agarose gel (8 ml, 640 mg) at 4° for 1 h, placed in a column, the solution was allowed to drain and the gel was washed with seven column volumes of MTPBS. The fusion protein was eluted with MTPBS containing reduced glutathione (5 mM) and fractions (2 ml) were collected. The protein, present in fractions 2-7, was collected (one band at Mr -52 K on SDS-PAGE), concentrated and the solvent was replaced with 50 mM Tris HCl pH 7.4 containing 2 mM DIT.
To obtain the unconjugated DHPRs the above experiment was repeated up to the stage at which the GS-Agarose gel was washed with seven volumes of MTPBS . The gel was then placed in a tube, MTPBS (5 ml) was added followed by human thrombin (100 f,1l, 100 NIH units) and genth' rotated for 2 h at room temperature then overnight at 4°. The gel was placed in a column, elut- ed with MTPBS and fractions (2 ml) were collected. The protein, in fractions 1-5 (one band at Mr -26 K on SDS-PAGE), was concentrated, the buffer replaced and stored as above. The fusion proteins and unconjugated DHPRs were stored in 50 mM Tris HCl pH 7.4 containing 2 mM DIT at -20°, preferably in the presence of 20 mM NADH to stabilise the active site. A Pharmacia Phast-System at 16° was used for SDS-PAGE. Protein concentrations were determined using the BioRad reagent (23) . Enzyme assays and kinetics were performed as before (22) .
Non-enzymic oxidation of NADH with quinonoid-6-methyl-7,8-dihydropterin at various pH values.-The non-enzymic rate of oxidation of NADH (100 11M) by quinonoid-6-methyl-7,S-dihydropterin (25 11M) was carried out at pH values of 6.0, 6.5, 7 .0, 7 .5 and S.O at 25°. Stock buffer was made from 1 M Tris buffer (1 ml, various pH values), horseradish peroxidase (1 ml, 0.2 mg, Sigma), hydrogen peroxide (15.7!J.l, 12% v/v) and H 2 0 (7 ml) and kept on ice. Stock buffer (900!J.l) and 6-methyl-5,6,7,Stetrahydropterin hydrochloride (24) (50!J.l, 5 mM in 4 mM Hel) were placed in the reaction cuvette and stock buffer (900!J.l) and water (50!J.l) in the reference cuvette, and the absorbance at 340 nm was observed until it was steady (i.e. with complete formation of the yellow colour of the quinonoid pterin, -0.5 min). NADH (50 Ill, 2 mM) was then added to the reference cuvette followed by a similar volume in the reaction cuvette to start the reaction. The initial rate of change of absorbance (using 0 .05 units for full deflection of the scale) was recorded. Since the concentration of the quinonoid pterin does not change in the first few seconds, the absorbance change is almost entirely due to the oxidation of NADH (e 6200 cm· 1 M· I ).
The pH profile is shown in Figure 1 . Similar absorbance measurements with reactions where NADH was replaced by H 2 0 (50!J.l) in both cuvettes were 2 to 4 orders of magnitude slower, i.e. the rate of rearrangement of quinonoid dihydropterin during the first 2-3 minutes was negligible compared with the oxidation rate of NADH at the respective pH values.
Results and Discussion
Reaction rates of reduction by hydride are Figure 1 ). In the enzyme catalysed reaction, the enzyme apparently provides the proton to enhance the reaction as well as to bind the substrates in proximate orientations to facilitate the reaction. Previous evidence with the rat reductase (3) inferred that the phenolic OH group of a tyrosine residue (146 for rat and 150 for human enzymes) at the active site is the protonating species. After hydride from NADH is transferred to N5 of the quinonoid-pterin, a transient tetrahydropterin anion species is formed. Table 1 lists the expected pKa values of the residues which we have altered at residue position 150 in human DHPR, assuming that they are not seriously perturbed by the environment at the active site, together with those of the intermediate tetrahydrobiopterin anion and the phenolic group of tyrosine (the residue in the natural enzyme).
Site-directed mutagenesis. -A general strategy (Scheme 2) had to be used for carrying out mutations at the active site as well as some mutations which have been identified in affected children in order to minimise our efforts. All mutations were between the Asc I and Sph I restriction sites of human DHPR cDNA (Figure 2) . We used the vector pAlter-l which possesses a gene for tetracycline resistance and a defective ~-lactamase gene (Ampicillin resistance, see Scheme 2) . The mutagenesis was carried out by annealing phosphorylated 31-mer oligonucleotides possessing the (Table 1) as primers, together with the phosphorylated Ampicillin repair nucleotide, to single stranded pAlter-1-hDHPR (6. 7 kilobases) into which the human DHPR cDNA has been inserted into the Bam HI -Sma I restriction sites. Synthesis of the complementary strand possessing the desired mutation and corrected 13-lactamase DNA sequence was performed using T4 DNA ligase and polymerase, and the plasmid DNA was transformed into competent BMH 71-18 mutS E.coli cells which suppress in vivo mismatch repair sequences (26, 27 ) and lead to high mutation frequencies. At least four out of five colonies that were selected (and usually five out of five colonies) possessed the desired mutation as shown by sequencing the affected regions of the respective isolated plasmid DNAs, after transformation into competent E.coli JM109 cells. It was now necessary to insert the mutation into an expression vector in order to produce the mutated DHPR. The plasmid DNAs from the selected clones (usually two clones) were cleaved with the restriction enzymes Asc I followed by Sph I which produced three DNA fragments, viz: 5800, 481 and 415 base pairs [see pAlter-1 DHPR in Scheme 2]. The 481 base pair fragment containing the mutation was isolated and ligated with the 5424 base pair fragment from the AscII SphI restriction enzyme digest from the expression vector pGEX2T-hDHPR (22) and transformed into competent JM109 cells. Selected colonies were grown and the supernatants from the disrupted cells were assayed for human DHPR and glutathione S-transferase (GST) activities. Usually all the selected colonies expressed human DHPR activity. The plasmids from these (five usually selected) were isolated and sequenced in the appropriate DNA regions. All the sequencing showPteridines/ Vol. 7/ No. 4 ed that the desired mutation had been selected.
Kinetic parameters of mutated DHPRs.-The kinetic parameters for various DHPRs with quinonoid dihydropterins and NADH had been previously evaluated from initial rate measurements at several concentrations of the first substrate and fixed high concentrations of the second substrate (assumed to be saturating) (13, 28) . Since high concentrations of quinonoid dihydropterins are inhibitory (1), and because mutant enzymes were used, the data were not strictly a valid assessment of substrate viability. In the present work, the initial rates from reactions with various concentrations of the first (quinonoid dihydropterin) and second substrate (NADH) (typically 25 to 36 duplicate measurements) but with the same concentration of DHPR were determined. The rates and concentrations data were all entered into computer programs (29) for various rate equations. All the data in this work gave two Km values (one for each substrate) and one Vmax value with acceptable errors (i.e. well within 10%), only when equation (1), but not equation (2) or other equations, was used. KiA is the dissociation constant of the first substrate A. These data suggested that the mechanism of the enzymic reactions of the mutant enzymes are similar to each other and to that of the natural enzyme, and that the dissociation constant (KiA) of the first substrate A is similar to its KmA value.
A considerable amount of data were measured for the free DHPRs and for the glutathione transferase (GST)-DHPR fusion proteins. Since thrombin digestion of the latter proteins was used to prepare the former DHPRs, then the N-terminal amino acid sequences of all the free mutated DHPRs are the same viz: GSAAAAGEAR. This sequence should be compared with that of the natural DHPR [N-terminal protected amino acid (1)], the human enzyme expressed from its cDNA in E.coli (MAAAAAAGEAR) and the rat ( 30) or mouse (22) enzymes expressed from their cDNA in E.coli (MAASGEAR for rat and mouse DHPR). It should be noted that the GST-fusion proteins and the thrombin cleaved free DHPRs are both dimeric proteins which appear as monomeric bands on SDS-PAGE . Comparison of the kinetic parameters, using q-6MeDHP or q-BH2 and NADH, of human DHPR (from brain or liver) and the DHPR expressed in E.coli as the fusion protein and then cleaved with thrombin see above) showed that the Km and kcat values \\-ere not significantly different (22) , indicating that the small differences in the sequences of the ~-terminal amino acids and in N-terminal amino acid protection (in the natural enzyme) cause o nly small differences in the kinetic parameters. :\ny large differences in the kinetic parameters between the mutated DHPRs should then be taken as being due almost entirely to the mutations made.
(a) Kinetic parameters of DHPRs with mutations a t residue ] 50. -The kinetic data for the D HPRs with mutations at the active site are listed in Tables 2 and 3 . It would be cumbersome to discuss all the parameters for individual mutations, so the two most important parameters, the kcat values, (i.e. the maximum velocities at saturating concentrations of substrates) and the kcat/ Km values [i.e. the first order rate constants at very low concentrations( «Km) of substrates] for q6MeDHP jNADH and q-BH 2 /NADH will discussed together. These are best represented graphically for comparison (Figures 3 and 4) . The kcat data in Table 2 are in Figure 3 . If we look at the kcat profile for q-6MeDHP jNADH we find that the substrates turnover considerably faster in the wild-type enzyme than in the other mutants. The Tyr 150Phe mutant causes large loss of activity which is partly restored by the more acidic Ser150 and further by the His150 replacements as would be expected if a proton source is required. The Tyr 150Glu mutation introduces a strongly acidic residue, which at the pH of the medium (7.4) should be in the anionic form and therefore cannot provide a proton to the anionic pterin sub- ..:..:
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His Ser Phe Gin strate. Unfortunately with the Try150Lys mutation it was not possible to isolate the pure DHPR due to extensive proteolysis. The Tyr 150Lys GST-DHPR fusion protein, however, could be obtained pure and the data (below) suggest that the corresponding DHPR should be at least as active as the Tyr150Phe mutant (see Table 3 ). Although the activities of some of the mutants were relatively low, it was possible to obtain accurate kinetic parameters by increasing the amounts of enzyme . It looks like the proton in such cases is supplied by some other acidic residue near the active site and less likely from the aqueous medium since the rates are still faster than the uncatalysed reactions. The proton from such neighbouring acidic groups may well be relayed via water molecules which are known to be present at the active site (see below) . The kcat profile for the natural substrate q-BH2 / NADH is somewhat different (Figure 3 ) from that for q-6MeDHP above . Here the turnover of the natural substrate (q-BH2) for the wild-type enzyme, the His, Ser and Phe mutants are roughly similar whereas that for the Glu mutant is slower. It has been proposed by Poddar and Henkin (31) and Randles (32) that the turnover of substrates in the enzyme mechanism may be dictated largely by a conformational change of the protein prior to a rapid protonation step. However, if the protonating residue is a very weak acid or is not acidic, then the turnover of substrates may be seriously impaired as perhaps in the case with q6MeDHP. The data with the natural substrate could be explained by the fact that the conformational change of the protein may be such that another protecting group near the active site, e .g . the y NH3+ of lysine-154 provides the proton directly or may be relayed via one or even two water molecules and this may not occur in the Glu-150 mutant. The assistance of Lys154 in the catalysis process had been previously identified (3). It is clear that the turnovers of the natural substrate with these mutant enzymes are different from those with the non-natural substrate (q6MeDHP), and it is therefore important when looking at the natural mutations, as in defective children (see below) that the data for the natural cofactor should be looked at, The Kcat/Km values of these mutant reductases are compared for q-6MeDHP and q-BH 2 in Figure 4 . The kcat/Km profile for q -6MeDHP somewhat resembles the kcat profile (Figure 3) , whereas the Kcat/Km profile for NADH is less steep, reflecting on the relative Km values, wherein the Km values for NADH are considerably smaller than those of q-6MeDHP for the mutant enzymes than for the wild-type enzyme (see Table 2 ).
The kcat/Km profile of these mutant reductases for q-BH 2 ( Figure 4 ) also resemble the kcat profile for q-6MeDHP but not for q-BH 2 ( Figure  3) , also reflecting on the relatively lower Km values ( Table 2 ). The kcat/Km profile for NADH (Figure 4 ), on the other hand, was a slightly exaggerated version of the kcat profile for q-BH2/ NADH (Figure 3) , with the Phe mutant exhibiting the largest value. These profiles reflect the subtle differences between the binding of q6MeDHP, q-BH 2 and NADH, and the effects of decreased protonating abilities of the amino acid residue at position 150, The data suggest that the effects of mutation may alter the rate limiting step which is infact the rate that one measures. It can be speculated that in the case of the Phe mutant with q-BH2 as substrate, the relatively larger kcat value (compared with the wild-type Tyr, see Figure 3) may well be due to the release of products caused by the hydrophobic nature of the benzene ring in Phel50 after proto nation by, perhaps, Lys 154.
The fusion proteins were available in high purity and their kinetic parameters for q-6MeDHP-NADH were similarly determined (Table 3) . When the parameters are compared with those of the free reductases they may provide some idea of the activities of the mutant reductases which could not be isolated in pure state because of extensive proteolysis. The kcat data ( Figure 5 ) and the kcat/Km data ( Figure 5) show that the re- lative activities of the mutant proteins are not strictly in the same order as for the unconjugated reductases. The His and Ser mutants turnover relatively faster than the wild-type enzyme which is quite different from the order observed with the respective unconjugated DHPR (see Figure 3) . The kcat/Km values on the other hand, with q6MeDHP as substrate, for the conjugated and unconjugated enzymes have similar profiles, although they are quite different with NADH as substrate. It should be noted that the Lys GST-fusion mutant turns over very slowly so the unconjugated DHPR is also unlikely to be anywhere nearly as active as the wild-type DHPR. The attachment of GST to DHPR clearly alters the active site of DHPR and care must be taken when using the activities of fusion proteins for comparison because they may not reflect the relative enzymic activities of the respective unconjugated proteins. Tables 4 and 5 . The child with the first mutation, Gly I5ISer exhibited a mild form of the disease (33) . This mutation is adjacent to Tyrl50 which we believe is the proton source for completing the enzymic reduction of the quinonoid pterin substrate. The kcat value of the reductase with the natural cofactor q-BH2 was even slightly larger (51.2 sec-I) than that for the wild-type enzyme (44.5 sec· l ), whereas the kcat/Km value was 13.8% of the value for the wild-type enzyme and is due to a tenfold increase in the Km value (Table 4) .
The non-natural cofactor (q-6MeDHP) exhibited the reverse trend, i.e. the kcat and kcat/Km values were 47% and 138% of the values for the wild-type enzyme. The kcat/Km values for NADH with q-BH2 and q-6MeDHP were respectively ll.8 and 3. 0% of the values of the wild-type reductase. The data on the whole demonstrate that although the mutation has affected the kinetic parameters, it has not seriously impaired enzyme activity and is consistent with the mild form of the disease. It should be noted that the kcat and Kcat/Km values for the mutant GST-DHPR fusion protein (Table 5) were consistently smaller compared with the values for the wild-type fusion protein and further confirm that the activities of fusion proteins can be quite different from those of the repective unconjugated proteins and should not be used for comparison or a correct indication of the severity of the disease.
The second mutation, Gly23Asp, has been found in a number of children (33) (34) (35) which in the homozygous patients manifests itself as a severe form of the disease (36) . The DHPR with this mu- tation was expressed in E. coli and was reported to be enzymically inactive when quinonoid 6,7 -dimethyl-7,8 (6H)-dihydropterin was used as cofactor (35) . We prepared this mutant DHPR because we felt that a child with complete absence of DHPR activity was unlikely to survive any length of time after birth. The kcat value of the mutant DHPR, which we prepared in this report, with q-6MeDHP as cofactor was indeed only 0 .13% (0 .3 sec· l ) of the kcat of the wild-type enzyme (227 sec I , see Table  4 ). However when the natural substrate q-BH 2 was used as cofactor the kcat of the mutant enzyme was as high a 35% (15.7 sec· l ) of the value with the wild-type enzyme (44.5 sec l ). This clearly shows that when comparing enzyme activities of mutant DHPRs, e.g. from fibroblast cultures, it is important that the natural cofactor q-BH2 should be used for measuring reductase activity and not any of the non-natural pterin cofactors if one is to make a rational comparison of enzyme activity with the severity of the lesion (see also above). The kcatjKm values also show the same disparity; with the natural cofactor (0.22%) being one order of magnitude a better substrate than q-6MeD HP (0 . 02%). The activity with respect to NADH is considerably reduced with respect to the wild-type DHPR as had already been stated (34) because the mutation Gly23Asp is at the NADH binding site of the reductase. The kcat/Km values with NADH for the unconjugated mutant DHPR and q-BH 2 and q-6MeDHP are 13.8 and 3% of the values for the wild-type enzyme.
The third mutation (37) , the insertion of a threonine at position 123, was also carried out in vitro in this study but the fusion protein was more difficult to purity and was contaminated Pteridines/ Vol. 7 / No. 4 with minor quannnes of other proteins. It was not possible to obtain the unconjugated mutant DHPR due to extensive proteolysis following thrombin cleavage. The fusion protein was enzymically active, but with decreased activity with respect to the wild-type fusion protein. The kcat and kcat/Km values in Table 5 are not corrected for protein impurities and the true values are therefore larger than those given in the table . The poor production of the fusion protein could well be because the threonine 123 insertion may inhibit dimerisation of DHPR as suggested previously from X-ray evidence (9) , making the protein susceptible to proteolysis in the environment used outside of the cell. The fusion protein would also be subject to inhibition to dimerisation (GST-DHPR fusion protein is a dimer in the natural state), but to a lesser extent because the glutathione S-transferase part of the molecule has a strong natural tendency to dimerise. The enzyme activity of the fusion protein is consistent with the clinical condition of the patient who is now a healthy teenager, albeit retarded due to delayed treatment (personal communication from Dr 1. W.
Earl and the late Dr Anthony H. Lipson ).
General remarks. -The enzymic activities of mutant DHPRs had been generally detennined by measuring the kinetics using non-natural pterin cofactors q-6MeDHP or q-6,7-Me2DHP and only occasionally the natural cofactor q-BH 2 • The kinetic data in the present communication show a disparity between the data obtained using the natural and the non-natural pterin cofactor, which in some examples is quite large. Since the natural cofactor is now readily commercially available, there should be no need to use non-natural cofactors when com-paring enzyme actIVItIes of mutant proteins, particularly when studying DHPR deficient patients. The data in this paper are mostly obtained using purified DHPR These are useful when studying the reaction mechanism. However when enzyme activities are to be correlated with the severity of DHPR deficiency disease it would be better to carry out the kinetics with crude extracts from tissues or cultured skin fibroblasts because the enzyme would be closer to its natural environment. Since the Krn values for q-BH2 and NADH vary with the mutation, and because DHPR is subject to substrate inhibition, an extended kinetic study as carried out above should be made, i.e. the rates for various concentrations of q-BH2 and NADH should be made using one concentration of enzyme, and the rates and concentrations should be computed to provide a Krn value for q-BH2 and one for NADH, and one maximum velocity value. For a thorough comparison of DHPR in defective fibroblasts it is also important to know what the levels of q-BH2 and NADH are so that appropriate comparisons of kcat or KcatjKrn values are made. The validity of kcat values for comparison rests on the assumption that both the q-BH 2 and NADH concentrations in the cells are at saturating levels.
The values of the kinetic parameters of the various GST-DHPR fusion proteins in this work do not follow the same order as the values of the corresponding unconjugated DHPRs. The kinetic data from fusion proteins in general should not therefore be used for assessing the relative activities of the respective unconjugated enzymes. However, fusion proteins which are DHPR active invariably provide unconjugated proteins which are DHPR active.
